Phase 3 N=905 Study to Evaluate Safety and Immunogenicity of nOPV2 at Different Intervals in Infants
Poliomyelitis
Primary: Seroconversion Rate at 1, 2 & 4 Weeks Interval — 253; 269; 277 Participants — p=0.05
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=60 Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics Study of Tolvaptan in Pediatric Congestive Heart Failure (CHF) Patients With Volume Overload
Pediatric Congestive Heart Failure (CHF) Patients With Volume Overload
Primary: Percentages of Subjects Whose Was Decreased by 1.7% or More Body Weight From Baseline — 22.8 percentage of participants
Phase 3 N=422 Efficacy and Safety of Pembrolizumab (MK-3475) With Lenvatinib (E7080/MK-7902) vs. Docetaxel in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) and Progressive Disease (PD) After Platinum Doublet Chemotherapy and Immunotherapy (MK-7902-008/E7080-G000-316/LEAP-008)
Metastatic Non-Small Cell Lung Cancer
Primary: Overall Survival (OS) — 11.3; 12.0 Months — p=0.4342
Phase 3 N=476 Impact of EMpagliflozin on Cardiac Function and Biomarkers of Heart Failure in Patients With Acute MYocardial Infarction
Acute Myocardial Infarction
Primary: Changes of Nt-proBNP (N-terminales Pro Brain Natriuretic Peptide) Levels — -84.9; -82.2 pg/mL
Phase 3 N=1,676 Using BCG to Protect Senior Citizens During the COVID-19 Pandemic
Covid19 · Non-specific Effects of Vaccines · Heterologous Immunity
Primary: Acute Infection — 424; 469; 212; 236 Events — p=< 0.05
Phase 3 N=270 A Study of Soticlestat as an Add-on Therapy in Children, Teenagers, and Adults With Lennox-Gastaut Syndrome
Lennox Gastaut Syndrome (LGS)
Primary: Percent Change From Baseline in Major Motor Drop (MMD) Seizure Frequency Per 28 Days During the Full Treatment Period — -6.69; -6.11 percent change — p==0.785
Phase 3 N=276 Extension Study of Vibegron in Men With Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia
Overactive Bladder
Primary: Number of Participants With Any Serious Adverse Event, and Treatment Emergent Adverse Event (>5%) — 2; 3; 17; 3 Participants
Phase 3 N=689 Study of Efficacy and Safety of Brolucizumab Versus Panretinal Photocoagulation Laser in Patients With Proliferative Diabetic Retinopathy
Proliferative Diabetic Retinopathy
Primary: Change From Baseline in Best-corrected Visual Acuity (BCVA) at Week 54 for the Study Eye — 0.2; -4.2 Letters Read — p=<0.001
Phase 3 N=152 Study of Durvalumab in Combination With Platinum and Etoposide for the First Line Treatment of Patients With Extensive-stage Small Cell Lung Cancer
Extensive-stage Small Cell Lung Cancer
Primary: Number of Participants With Incidence of Grade 3 or Higher Adverse Events (AEs) — 91 Participants
Phase 3 N=438 Impact of Very Low Nicotine Content Cigarettes in a Complex Marketplace
Tobacco Smoking · Nicotine Dependence
Primary: Cigarettes Per Day (CPD) — 7.05; 12.95 cigarettes per day
Phase 3 N=554 Study of ThermoDox With Standardized Radiofrequency Ablation (RFA) for Treatment of Hepatocellular Carcinoma (HCC)
Hepatocellular Carcinoma
Primary: Overall Survival (OS) — 58.06; NA Months
Phase 3 N=426 A Study To Assess the Safety and Effects of OnabotulinumtoxinA (BOTOX) Intramuscular Injection in Adult Participants With Platysma Prominence
Platysma Prominence
Primary: Number of Participants With Adverse Events — 43; 34 Participants
Phase 3 N=620 Effect of NOV03 on Signs and Symptoms of Dry Eye Disease Associated With Meibomian Gland Dysfunction (Mojave Study)
Dry Eye Disease
Primary: Change From Baseline in Total Corneal Fluorescein Staining Score (NEI Scale) in the Study Eye at Day 57 — -2.3; -1.1 units on a scale
Phase 3 N=120 Metvix Photodynamic Therapy (PDT) Versus Cryotherapy in Participants With Primary Superficial Basal Cell Carcinoma
Superficial Basal Cell Carcinoma
Primary: Percentage of Participants With Histologically Confirmed Patient Complete Response (CR) 3 Months After Last Metvix PDT or Cryotherapy Cycle — 92; 90 percentage of…
Phase 3 N=1,453 ACTIV-6: COVID-19 Study of Repurposed Medications - Arm F (Montelukast)
Covid19
Primary: Time to Sustained Recovery in Days — 10; 10 days